Wednesday, July 8, 2026

Patent intelligence · US

US 11325916

Spiropyrrolidine derived antiviral agents

granted A61KA61K31/404A61PA61P31/14
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 16
Applicant portfolio 218
Patent details — US 11325916
Jurisdiction
US
Status
granted
Grant date
May 10, 2022
Expiration
May 5, 2042
Claims
15
CPC classes
A61K, A61K31/404, A61P, A61P31/14
View on Google Patents ↗

Quick answer

US 11325916 (Spiropyrrolidine derived antiviral agents) is held by Enanta Pharmaceuticals, Inc.. Status: granted. Granted May 10, 2022. Expires May 5, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
15
CPC classes
A61K, A61K31/404, A61P, A61P31/14

More from Enanta Pharmaceuticals, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12384753

    17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof

    Enanta Pharmaceuticals, Inc. · Expires Aug 7, 2045

    granted
  2. US 12358921

    Antiviral heterocyclic compounds

    Enanta Pharmaceuticals, Inc. · Expires Jul 10, 2045

    granted
  3. US 12297209

    Benzodiazepine derivatives as RSV inhibitors

    Enanta Pharmaceuticals, Inc. · Expires May 8, 2045

    granted
  4. US 12281140

    Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof

    Enanta Pharmaceuticals, Inc. · Expires Apr 17, 2045

    granted
  5. US 12268694

    Combination pharmaceutical agents as RSV inhibitors

    Enanta Pharmaceuticals, Inc. · Expires Apr 3, 2045

    granted
  6. US 12264159

    Functionalized heterocycles as antiviral agents

    Enanta Pharmaceuticals, Inc. · Expires Mar 27, 2045

    granted
  7. US 12162857

    Antiviral compounds

    Enanta Pharmaceuticals, Inc. · Expires Dec 5, 2044

    granted
  8. US 12145941

    Heterocyclic antiviral agents

    Enanta Pharmaceuticals, Inc. · Expires Nov 14, 2044

    granted

Frequently asked questions

What is US patent 11325916?

US 11325916 (Spiropyrrolidine derived antiviral agents) is held by Enanta Pharmaceuticals, Inc.. Status: granted. Granted May 10, 2022. Expires May 5, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11325916?

Enanta Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 218 pharmaceutical patents for this assignee.

When does US 11325916 expire?

Our index shows an expiration date of May 5, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.